Skip To Main Content
Danielle Ternyila on Muck Rack

Danielle Ternyila

  • Digital & Multi-Media Marketing Manager, Acrotech Biopharma, LLC
New Jersey
As seen in: ONCOLOGY journal, CURE Magazine, OncLive, Targeted Oncology, Urology Times, Oncology Nursing News
Published Novelist ~ Digital Marketing ~ Proud @RowanUniversity Writing Arts Alumni
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Danielle

Contact Danielle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patients With Esophageal Squamous Cell Carcinoma Respond to Camrelizumab/Apatinib Combo in Second-Line Setting

|
By Danielle Ternyila
| ONCOLOGY journal Verified
Data presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma. Results of a single-arm, open-label phase 2 study revealed positive clinical results coupled with an acceptable safety profile for camrelizumab (SHR-1210) plus apatinib (Rivoceranib) as therapy in the second-line setting for patients with esophageal squamous cell carcinoma (ESCC).
Open in Who Shared Issue with article?

Addition of Navitoclax Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

|
By Danielle Ternyila
| ONCOLOGY journal Verified
Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.
Open in Who Shared Issue with article?

Enzalutamide Yields PFS Benefit Across nmCRPC Subgroups

|
By Danielle Ternyila
| ONCOLOGY journal Verified
Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.
Open in Who Shared Issue with article?
See all 19 licensed articles (658 Total)